Brainomix is a medical imaging company specializing in AI-powered imaging biomarkers for stroke and lung diseases. Originating as a spin-out from the University of Oxford, it offers automated imaging analysis platforms like Brainomix 360 for stroke and e-Lung for ILD, IPF, and other lung conditions, used by healthcare systems worldwide to support precision medicine and treatment decisions. The company focuses on transforming radiology workflow with validated biomarkers to improve diagnosis, triage, and patient outcomes across global clinical communities.
No recent news for this company.